期刊文献+

论毒邪与骨髓增生异常综合征 被引量:8

Discussion on Pathogenic Toxin and Myelodysplastic Syndrome
下载PDF
导出
摘要 通过回顾总结前人学说和相关文献中有关毒邪的涵义、分类、致病机理等理论,结合骨髓增生异常综合征(MDS)的病因病机及中医临床证治特点,阐述MDS的发生与"内毒"和"外毒"的关系,指出毒邪既是MDS的重要致病因素又是疾病过程中的病理产物,在MDS不同阶段必须权衡毒邪内停之轻重,适时、得当地采用清解邪毒法治疗,可以抑制骨髓异常增生,诱导造血干细胞的分化,促进MDS骨髓的正常造血。 We summarized the predecessors' academic views and reviewed the related literature of the theory of pathogenic toxin about its meaning, categories and pathogenesis, analyzed the etiopathogenesis and the traditional Chinese medical syndrome differentiation and treatment of myelodysplastic syndrome (MDS), and then explored the relationship between the occurrence of MDS and external and internal toxin. It is pointed out that pathogenic toxin is not only one of the important pathogenic factors but also the pathological product in the progress of MDS. Judging the severity of pathogenic toxin in different stages of MDS, and then adopting the timely and proper treatment of removing and dispelling toxin can suppress the hyperplasia of bone marrow, induce the differentiation of hematopoietic stem cell, and promote normal hematopoiesis in bone marrow of MDS patients.
作者 曾庆 陆嘉惠
出处 《新中医》 CAS 北大核心 2011年第1期1-3,共3页 New Chinese Medicine
基金 上海市科技人才计划项目资助(编号:09QA1405700) 上海市卫生局资助(编号:2006Q001L)
关键词 骨髓增生异常综合征 毒邪 中医病因和病机 清解邪毒 Myelodysplastic Syndrome Pathogenic Toxin Etiopathogenesis of Traditional Chinese Medicine Removing and Dispelling Toxin
  • 相关文献

参考文献12

二级参考文献66

  • 1朱文锋.证名规范研究之我见(续)[J].辽宁中医杂志,1987(2):17-19. 被引量:12
  • 2胡涛,师晓东,冯燕玲,刘嵘,李君惠,陈静,王天有.三种血小板减少症患儿骨髓巨核细胞比较[J].中华儿科杂志,2005,43(3):183-187. 被引量:7
  • 3崔文成.甘温除热法管见[J].中医杂志,1994,35(8):460-462. 被引量:11
  • 4Cheson BD, Bennett JM, Kantariian H, et al. Report of an International Working Group to standardize response criteria for myelodysplastie syndromes. Blood, 2000,96(12),3671-367.
  • 5Garzon R, Ellison R, Kirkhart B, et al. Updated safety experience with Trisenox (arsenic trioxide) injection. Presented as the 8th Congress of the European hematology Association, 12-15 June,2003, Lyon,France.
  • 6List A, Beran M, Dipersio J,et al, Opportunities for Trisenox(arsenic trioxide) in the treatment of myelodysplastic syndromes.Leukemia, 2003,17(8) : 1499-1507.
  • 7Vey N, Drefus F, Guerci A, et al. Trisenox (arsenic trioxide) in patients (pts) with myelodysplastic Syndromes (MDS) : preliminary results of a phase 1/2study. Presented as a poster at the 7th international Symposium on Myelodysplastie Syndromes, Paris,France, May 15-18,2003.
  • 8Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndrome. Leukemia,2002,16(1):1-6.
  • 9Zorat F, Sherry V, Dutt D,et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndrome. Br J Haematol, 2001, 115(4) :881-894.
  • 10Raza A, Meyer P, Dutt D, et al, Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes, Blood, 2001, 98 (4):958-965.

共引文献113

同被引文献87

引证文献8

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部